The anti-tumor immune response involves a series of complex steps mediated by various immune cells and signaling molecules.

Therapies market, valued at USD 16.7 million in 2024, is expected to register robust revenue CAGR of 44.6%.Request free copy of this report: 13, 2026- The growing incidence of autoimmune disorders ...

To thrive beyond rare disease, cell and gene therapy developers must scale-up manufacturing and commercialisation.

Hong Kong-based biomed pioneer is at the forefront in a global race to develop cell and gene treatments for cancers and other ...

The interferon regulatory factor (IRF) family of transcription factors, pivotal for initiating antiviral type I interferon ...

Approval of ANKTIVA was granted for BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ, with ...

Johnson & Johnson announces positive results from phase 3 MajesTEC-9 study of Tecvayli in patients with multiple myeloma: Raritan, New Jersey Friday, January 16, 2026, 10:00 Hrs [ ...

Sherry Gu, Executive Vice President and CTO at WuXi Biologics, explains the critical challenges of developing bispecific ...

The 2025 American Society of Hematology (ASH) meeting in December presented a clear message: scientific innovation and ...

Single-use systems streamline CGT manufacturing by reducing cleaning validation and enabling quick changeovers, essential for ...

Retinoic acid suppresses immune defenses against cancer, but a new drug KyA33 boosts vaccine success and slows tumor growth ...

CK0804, a regulatory T cell therapy, received FDA orphan drug designation for myelofibrosis, supporting rare disease treatment development. Clinical study results showed significant reductions in ...